CD1-restricted T cells and tumor immunity.
CD1d-restricted T cells (NKT cells) are potent regulators of a broad range of immune responses. In particular, an abundance of research has focussed on the role of NKT cells in tumor immunity. This field of research has been greatly facilitated by the finding of agonist ligands capable of potently stimulating NKT cells and also animal models where NKT cells have been shown to play a natural role in the surveillance of tumors. Herein, we review the capability of NKT cells to promote the rejection of tumors and the mechanisms by which this occurs. We also highlight a growing field of research that has found that NKT cells are capable of suppressing anti-tumor immunity and discuss the progress to date for the immunotherapeutic use of NKT cells.
Swann
J B
JB
Department of Microbiology and Immunology, University of Melbourne, 3010 Parkville, Victoria, Australia.
Coquet
J M C
JM
Smyth
M J
MJ
Godfrey
D I
DI
D000818:Animals; D018949:Antigens, CD1 / Q000378:metabolism*; D017321:Clinical Trials, Phase I as Topic; D004195:Disease Models, Animal; D005699:Galactosylceramides / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy
D018949:Antigens, CD1; D005699:Galactosylceramides; C493154:alpha-galactosylceramide